Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q2
Score: 0.5
صح
خطأ
Q3
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q4
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q5
Score: 0.5
A- phase -1
B- phase- 2
Q6
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q7
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q8
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q9
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q10
Score: 0.5
Q11
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q12
Score: 0.5
Q13
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q14
Score: 0.5
Q15
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q16
Score: 0.5
صح
خطأ
Q17
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q18
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q19
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q20
Score: 0.5
صح
خطأ
Q21
Score: 0.5
صح
خطأ
Q22
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q23
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Q24
Score: 0.5
Q25
Score: 0.5
صح
خطأ
Q26
Score: 0.5
Q27
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q28
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q29
Score: 0.5
صح
خطأ
Q30
Score: 0.5
Q31
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q32
Score: 0.5
Q33
Score: 0.5
صح
خطأ
Q34
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q35
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q36
Score: 0.5
صح
خطأ
Q37
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q38
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q39
Score: 0.5
صح
خطأ
Q40
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q41
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q42
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q43
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q44
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q45
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q46
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q47
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q48
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q49
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q50
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q51
Score: 0.5
صح
خطأ
Q52
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q53
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q54
Score: 0.5
صح
خطأ
Q55
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q56
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q57
Score: 0.5
صح
خطأ
Q58
Score: 0.5
صح
خطأ
Q59
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q60
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q61
Score: 0.5
Q62
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q63
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q64
Score: 0.5
صح
خطأ
Q65
Score: 0.5
Q66
Score: 0.5
صح
خطأ
Q67
Score: 0.5
صح
خطأ
Q68
Score: 0.5
A- animal
B- human
C- in vivo
Q69
Score: 0.5
A- FDA
B- NMR
C- IND
Q70
Score: 0.5
صح
خطأ
Q71
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q72
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q73
Score: 0.5
صح
خطأ
Q74
Score: 0.5
Q75
Score: 0.5
Q76
Score: 0.5
صح
خطأ
Q77
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q78
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Q79
Score: 0.5
صح
خطأ
Q80
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert